Subtopic Deep Dive
Glioblastoma Molecular Classification
Research Guide
What is Glioblastoma Molecular Classification?
Glioblastoma molecular classification stratifies tumors using IDH, EGFR, NF1, and 1p/19q alterations via integrated multi-omics for prognosis and therapy selection.
The 2016 WHO classification integrates molecular markers like IDH mutations with histology (Louis et al., 2016, 15475 citations). IDH1/2 mutations define major glioma subtypes and occur in most lower-grade gliomas (Yan et al., 2009, 5790 citations). Comprehensive genomic analysis reveals IDH, 1p/19q, and TP53-based classes superior to histology (Brat et al., 2015, 3149 citations).
Why It Matters
Molecular classification enables precision medicine by identifying IDH-mutant patients for targeted therapies, improving survival predictions beyond histology. Yan et al. (2009) showed IDH mutations in 70-80% of grade II-III gliomas, guiding prognosis. Louis et al. (2016) established WHO standards adopted globally, stratifying glioblastoma for EGFR-amplified or NF1-altered cases responsive to specific drugs. Brat et al. (2015) demonstrated molecular classes predict outcomes better, influencing EANO guidelines (Weller et al., 2020).
Key Research Challenges
Heterogeneity in multi-omics integration
Combining genomic, epigenomic, and transcriptomic data reveals inconsistent subtypes across datasets. Turcan et al. (2012) linked IDH1 mutations to hypermethylation, but EGFR/NF1 alterations vary (1934 citations). Standardized classifiers remain elusive (Brat et al., 2015).
Prognostic classifier validation
Molecular signatures like IDH/1p19q require large cohort validation for clinical use. Yan et al. (2009) identified mutations, but survival models need refinement (5790 citations). Louis et al. (2016) notes gaps in glioblastoma-specific markers.
Translating subtypes to therapies
Matching IDH-wildtype EGFR-amplified tumors to drugs faces resistance issues. Tan et al. (2020) reviews state-of-art, highlighting NF1 subtype challenges (1953 citations). Weller et al. (2020) guidelines stress personalized trial needs.
Essential Papers
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis, Arie Perry, Guido Reifenberger et al. · 2016 · Acta Neuropathologica · 15.5K citations
<i>IDH1</i>and<i>IDH2</i>Mutations in Gliomas
Hai Yan, D. Williams Parsons, Genglin Jin et al. · 2009 · New England Journal of Medicine · 5.8K citations
Mutations of NADP(+)-dependent isocitrate dehydrogenases encoded by IDH1 and IDH2 occur in a majority of several types of malignant gliomas.
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
Daniel J. Brat, Roel G.W. Verhaak, Kenneth D. Aldape et al. · 2015 · New England Journal of Medicine · 3.1K citations
The integration of genomewide data from multiple platforms delineated three molecular classes of lower-grade gliomas that were more concordant with IDH, 1p/19q, and TP53 status than with histologic...
The epidemiology of glioma in adults: a "state of the science" review
Quinn T. Ostrom, Luc Bauchet, Faith G. Davis et al. · 2014 · Neuro-Oncology · 2.2K citations
Gliomas are the most common primary intracranial tumor, representing 81% of malignant brain tumors. Although relatively rare, they cause significant mortality and morbidity. Glioblastoma, the most ...
Management of glioblastoma: State of the art and future directions
Aaron C. Tan, David M. Ashley, Giselle Y. López et al. · 2020 · CA A Cancer Journal for Clinicians · 2.0K citations
Abstract Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for patients with this disease is poor, with a median survival of <2 years. There is a slight predo...
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Şevin Turcan, Daniel Rohle, Anuj Goenka et al. · 2012 · Nature · 1.9K citations
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017
Quinn T. Ostrom, Nirav Patil, Gino Cioffi et al. · 2020 · Neuro-Oncology · 1.9K citations
Abstract The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control (CDC) and National Cancer Institute (NCI), is the largest population-b...
Reading Guide
Foundational Papers
Start with Louis et al. (2016) for WHO standards, then Yan et al. (2009) for IDH discovery, and Turcan et al. (2012) for epigenetic mechanisms to build core classification framework.
Recent Advances
Study Brat et al. (2015) for multi-omics integration, Tan et al. (2020) for therapy links, and Weller et al. (2020) for EANO guidelines on clinical translation.
Core Methods
IDH mutation testing via sequencing (Yan et al., 2009); multi-platform genomic analysis (Brat et al., 2015); methylation profiling for hypermethylator phenotype (Turcan et al., 2012).
How PapersFlow Helps You Research Glioblastoma Molecular Classification
Discover & Search
Research Agent uses searchPapers('glioblastoma IDH EGFR NF1 classification') to find Louis et al. (2016), then citationGraph reveals 15k+ citing papers and findSimilarPapers uncovers Yan et al. (2009) IDH work. exaSearch queries 'NF1 altered glioblastoma subtypes' for rare variants.
Analyze & Verify
Analysis Agent applies readPaperContent on Brat et al. (2015) to extract IDH/1p19q classes, verifyResponse with CoVe checks mutation frequencies against Yan et al. (2009), and runPythonAnalysis computes survival Kaplan-Meier curves from supplementary data using pandas. GRADE grading scores evidence strength for WHO classifiers.
Synthesize & Write
Synthesis Agent detects gaps in NF1 subtype therapies via contradiction flagging across Tan et al. (2020) and Weller et al. (2020), while Writing Agent uses latexEditText for classifier tables, latexSyncCitations for 10+ papers, latexCompile for manuscripts, and exportMermaid for subtype decision trees.
Use Cases
"Run survival analysis on IDH mutant vs wildtype glioblastoma cohorts from recent papers"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas Kaplan-Meier plot from Brat et al. 2015 data) → matplotlib survival curve output with p-values.
"Draft LaTeX review on WHO 2016 glioblastoma classification updates"
Synthesis Agent → gap detection → Writing Agent → latexEditText (intro section) → latexSyncCitations (Louis et al. 2016, Yan et al. 2009) → latexCompile → PDF with figures.
"Find code for glioma multi-omics classifiers"
Research Agent → paperExtractUrls (Brat et al. 2015) → Code Discovery → paperFindGithubRepo → githubRepoInspect → R script for IDH subtype prediction shared with researcher.
Automated Workflows
Deep Research workflow scans 50+ papers on 'IDH EGFR NF1 glioblastoma' via searchPapers → citationGraph → structured report with GRADE-scored subtypes from Louis et al. (2016). DeepScan applies 7-step CoVe analysis to verify Yan et al. (2009) mutation rates across Brat et al. (2015). Theorizer generates hypotheses on NF1-targeted therapies from Tan et al. (2020) literature synthesis.
Frequently Asked Questions
What defines glioblastoma molecular classification?
It uses IDH-wildtype status, EGFR amplification, and NF1 alterations per WHO 2016 (Louis et al., 2016), distinguishing from IDH-mutant lower-grade gliomas (Yan et al., 2009).
What are key methods in this subtopic?
Integrated multi-omics classifiers combine genome-wide data for IDH, 1p/19q, TP53 status (Brat et al., 2015); IDH1 mutation induces hypermethylator phenotype (Turcan et al., 2012).
What are foundational papers?
Yan et al. (2009, 5790 citations) discovered IDH1/2 mutations; Louis et al. (2016, 15475 citations) set WHO standards; Turcan et al. (2012, 1934 citations) linked IDH to epigenetics.
What open problems exist?
Validating NF1/EGFR classifiers for therapy (Tan et al., 2020); standardizing multi-omics across populations (Weller et al., 2020); overcoming intratumor heterogeneity.
Research Glioma Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Glioblastoma Molecular Classification with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Glioma Diagnosis and Treatment Research Guide